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Abstract
A model lipid membrane consisting of a monolayer of dioleoyl phosphatidylcholine (DOPC) adsorbed onto a Hg electrode has been used
to study the interaction between the lipid and different formulations of Amphotericin B (AmB) [FungizoneR (FZ), Heated Fungizone (HFZ),
and AbelcetR]. The lipid organizational order was measured by electrochemical methods [capacitance and metal ion (Tl+) reduction],
characterizing the change in lipid order due to interaction with the drug. The mean size and number density of pores formed in the monolayer
were estimated by fitting the reduction current transients to a random array of microelectrode model. This method was shown sensitive for
investigation of the interaction of drugs with the DOPC monolayer. Abelcet was found to have a smaller disruptive effect on lipid order than
FZ and HFZ. The formulations used to solubilize the AmB were also studied. Sodium deoxycholate used as a solubilizer in FZ displayed
significant influence on lipid order similar to that observed for Abelcet. The lipid complex, used in Abelcet, did not significantly perturb the
DOPC monolayer order. The lipid complex used in Abelcet may have an annealing or healing effect that buffers the disruption possible due
to AmB. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Amphotericin B (AmB) is a polyene macrolide antibiotic
used to combat fungal infections in patients with impaired
immune systems. Studies in this area are important because
of the increased occurrence of fungal infections [1,2]. This
increase is due in part to improved recognition and diag-
nosis of fungal infections, but also to the prolonged survival
of patients with defects in their host defense mechanisms,
including patients with cancer, organ transplant recipients,
diabetics, and patients with AIDS [3,4]. In these patients,
invasive fungal infections may account for as many as 30%
of deaths [4,5].
The treatment of systemic fungal infections has relied
upon drugs that tend to have significant in vivo toxicity.
AmB’s use is limited due to its systemic side effects [6,7]
(fever and chills) and renal toxicity (which limits the
duration of therapy). The observed toxicity results from a
similarity of drug interaction with mammalian and fungal
cells, and its effectiveness as therapy relies upon the
selectivity of the destructive interaction toward fungal cells.
The mechanism of action of polyene antibiotics and the role
played by the components of the cell membrane (lipid,
sterol, membrane protein) is still under discussion, but
generally, interaction between the sterol and the antibiotic
is considered important [6,8]. The major sterol component is
cholesterol for the mammalian cell and ergosterol for the
fungal cell. Differences in the interaction between the AmB
and each sterol have been proposed [6,7] to be the origin of
the effectiveness of the treatment although this sterol
hypothesis is still under study.
It is believed that AmB initially adsorbs onto the cell
membrane and forms non-conductive pre-pore complexes
[9,10]. AmB then interacts with the sterol in the cell
membrane creating ion channels and pores resulting in cell
lysis and death. This process has been recently studied using
AFM [11]. Studies show that the efficacy of AmB is based
on its strong interaction with ergosterol in fungal mem-
branes as compared to the weaker interaction with choles-
terol in mammalian membranes, resulting in a differentiated
response [9].
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AmB is amphipathic having low solubility in water. It
exists in many forms (monomers and aggregated structures)
in aqueous media for concentrations above 1 AM, the critical
aggregate concentration [9]. Due to its amphipathic nature,
AmB requires solubilization for administration. Fungizone
(FZ) (Bristol-Myers Squibb, New Jersey) is the most widely
used formulation in which AmB is complexed with a
detergent (deoxycholate). It has been suggested that the
aggregated forms of the drug are toxic to both ergosterol-
and cholesterol-containing membranes, while the monomer
specifically porates ergosterol-containing membranes. The
absorption spectra of monomer and self-associated forms of
AmB are different and a blue-shifted band has been ob-
served for aggregated molecules [12]. Heating the AmB/
deoxycholate complex (20 min at 70 jC) creates a super-
aggregated form of AmB, Heat-Treated Fungizone (HFZ),
which appears to have a reduced toxicity [13,14]. One
hypothesis explaining the HFZ results suggests that the
super-aggregated form of AmB does not form channels in
the membrane, unlike the aggregated form, but exists near
the membrane, releasing monomers of AmB which selec-
tively damage fungi membranes, thereby maintaining the
drugs efficacy. AmB complexed with lipids (Abelcet) or
contained within liposomes have decreased toxicity [15–
19]. These formulations have similar efficacy to FZ but
remain expensive and inaccessible to most patients.
Although AmB has been used clinically for many years,
basic physical–chemical data on its aggregation state in
solution and the method of incorporation into the cell
membrane are not clear. For example, the sterol hypothesis
claims that the presence of sterol is critical to the formation
of the pore. Some studies have shown that pores are created
even in sterol-free membranes [20,21] and recently, pores
have been found in sterol-free membranes that were under
osmotic stress [22]. These conflicting observations and
hypotheses demonstrate the need for tools and simple
experimental models for measurement of the drug/lipid/
sterol interaction under varying conditions.
A number of different avenues have been taken toward
understanding the molecular interactions that play a role in
the mechanism of AmB action on fungal and mammalian
cell membranes. These generally fall into two categories:
floating monolayer (Langmuir trough) studies and studies
on lipid bilayers (vesicles or BLM). In both cases, basic
physical–chemical data regarding the interactions of the
drug with the lipid and sterol components of the membrane
have been obtained. Characterization of interactions
between AmB, lipid and sterol was performed in a Lang-
muir trough [23–31]. These fundamental studies were
useful for defining the nature of AmB interaction with lipid
and sterol, although a floating monolayer is not a mimic of a
biological membrane.
The influence of AmB on lipid bilayers, either as BLM or
liposomes, sterol-free or containing either cholesterol or
ergosterol was also extensively studied [20,22,32–39].
Formation of ion-specific and nonspecific pores in the lipid
bilayer was observed through measurement of ionic or
molecular flux. The type and concentration of sterol in the
membrane was also manipulated. These studies confirmed
the formation of pores in the lipid bilayers due to sterol/
AmB complex. Pores were also observed in sterol-free
liposomes that were subjected to osmotic stress, indicating
a need for more fundamental studies.
The interaction of the anti-fungal drugs with membranes
in vivo is a complicated problem and model membranes
facilitate the investigation of these interactions. We shall
describe an electrochemical technique for studying the lipid/
AmB interaction performed on dioleoyl phosphatidylcho-
line (DOPC) monolayer. A DOPC monolayer floating on an
aqueous solution is deposited onto a Hg drop electrode. The
DOPC monolayer models the outer leaflet of a biological
membrane since the alkyl tails are adsorbed onto the metal
surface and the head groups are in contact with the aqueous
phase [40,41]. Deposition onto a conductive surface allows
the use of electrochemical techniques for characterization
and control of the adsorbed monolayer. The electrochemical
properties of phospholipid monolayers of DOPC adsorbed
onto mercury surfaces have been investigated using capaci-
tance measurements [40–45]. An increase in the minimum
capacitance will indicate an increase in the defect content of
the adsorbed lipid layer, which can be correlated to inter-
action with compounds in the aqueous phase. In addition,
these layers display multiple states that interconvert, at
specific potentials, through phase transitions that are man-
ifested as peaks in the capacitance measurements. These
peaks are sensitive to changes in the organization of the
adsorbed layer, to the composition of the layer and to in-
teraction with surface active agents in solution, such as
therapeutic drugs like AmB. The height and width of
these peaks contain information about the kinetics of the
adsorption/desorption or reorientation (condensation) proc-
ess [46–48] and therefore can be used as an indirect
measurement of the organizational properties of the ad-
sorbed lipid layer. These tools are particularly useful since
slight defects in the lipid layer will be reported by the
electrochemical measurements, allowing us to investigate
the pre-pore formation events.
The integrity of the adsorbed DOPC layer and the phase
transition regions was further characterized utilizing metal
ion (Tl+) reduction. These metal ions are reduced at the Hg
surface to form an amalgam, but first they must penetrate
through the lipid layer. This affords us the ability to measure
the permeability of the lipid layer. In addition, the potential
drop across the adsorbed layer controls this permeability
[42]. The lipid layer phase transition is preceded by the
creation of various defect regions that allow the metal ion
facile access to the Hg surface. The creation of these defects
is due to stress caused by the imposed potential drop across
the monolayer, not unlike the effects of osmotic stress. In
both cases, pores are created in the lipid layer, due to osmotic
or interfacial tensions. The rate of the metal ion penetration
through the layer (measured as current) is correlated to the
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size and density of pores in the lipid layer. The creation of
these pores is a function of the lipid layer’s organizational
properties that are modified by interaction with the drug.
We describe the use of a model membrane system to
study three different formulations of AmB and their inter-
action with the lipid monolayer. The electrochemical
response of the lipid/Hg model was utilized to characterize
the changes in the monolayer organization due to interaction
with AmB formulations. The model system is a monolayer
of DOPC, and as such, is not an ideal model of a cell
membrane. The advantage using this model is in its char-
acterization of lipid organization and of the subtle changes
that may exist due to peripheral interaction with the drug in
solution. In addition, the size and density of pores created
through a combination of interaction with the drug and the
potential drop across the DOPC layer can be extracted. The
questions that can be addressed with this methodology
include: how do FZ, HFZ and Abelcet modify sterol-free
monolayers; how can this interaction be quantified and what
new insights can be gained on the possible mechanism of
action (mechanism of this disruption).
2. Materials and methods
2.1. Formulation preparation
FZ was prepared according to manufacturer’s directions:
FZ was supplied as a lyophilized powder consisting of 50 mg
AmB, 41 mg sodium deoxycholate, and 20.2 mg sodium
phosphates made up to 10 ml volume with MilliQ water. This
stock solution was diluted 5:1 with MilliQ water before use.
HFZ was prepared by heating the diluted FZ solution to 70
jC for 20 min. Sodium deoxycholate (Sigma ultra grade)
solution (0.85 mg/ml) was prepared in MilliQ water.
AbelcetR (The Liposome Company, New Jersey) was sup-
plied as 20 ml volume containing 100 mg AmB, 68 mg L-a-
dimyristoylphosphatidylcholine (DMPC), 30 mg L-a-dimyr-
istoylphosphatidylglycerol (DMPG), and 180 mg sodium
chloride used as received. An Abelcet blank was prepared to
have the same composition as Abelcet, but without the AmB.
DMPC and DMPG were from Avanti Polar Lipids
(Alabaster, AL) and KCl (Fluka) was used instead of NaCl.
AmB is used as a generic term to describe any of FZ, HFZ,
and Abelcet. AmB was introduced into the cell by injecting
by syringe an aliquot into the electrolyte (70 ml of 0.1 M
KCl) and stirring gently for 30 s with a magnetic stir bar. FZ
and Abelcet concentrations were expressed as percentages of
the normal adult therapeutic dose (TD) specified by the
manufacturer (0.5 and 5 mg l1, respectively) in an attempt
to mimic physiological conditions. The actual concentrations
of AmB in the subphase at the TD were 0.54 and 5.4 AM,
respectively. Sodium deoxycholate was introduced in con-
centrations equivalent to the deoxycholate concentration in
each percentage therapeutic dose of FZ. The same procedure
was used for lipid mixture that comprises the Abelcet blank.
2.2. Electrochemical apparatus and methods
A monolayer of DOPC (semi-synthetic grade, Lipid
Products UK) was formed on the surface of 0.1 M KCl
(Fluka, calcined 500 jC, prepared in 18.2 MV MilliQ water
and deaerated with argon) as described previously [49,50].
Briefly, 8 Al of 2 mg/ml DOPC dissolved in pentane is
introduced onto the surface of deaerated electrolyte. The
pentane evaporates leaving a monolayer of DOPC in
equilibrium with bulk phase DOPC present as droplets.
The DOPC monolayer exists at its equilibrium spreading
pressure (Pe=50 mN m1) which is the greatest surface
concentration that can be achieved while remaining in a
thermodynamically stable phase [51]. This procedure
ensures a consistent DOPC surface concentration, even if
material is lost to the walls of the glass cell. The floating
lipid monolayer is deposited onto a Hg drop (Fig. 1) under
potential control by passing the drop through the DOPC/
electrolyte surface. A hanging drop mercury electrode
(WK2, Polish Academy of Sciences), filled with triple
distilled mercury (DFG Mercury) was used. The capillaries
were silanized using 4% dimethyl-dichlorosilane in tri-
chloroethane before filling with Hg. The Hg-filled capillary
was cleaned before use by dipping into a sulfuric/nitric acid
mixture. This DOPC/Hg interface was configured as the
working electrode in a three-electrode arrangement. The
SCE reference electrode was connected to the working
solution through a salt bridge. The counter electrode was a
platinum coil cleaned by flame annealing.
The electrochemical measurements were made with a
potentiostat (FHI) used with a lock-in amplifier (PAR 5210)
and data were recorded with a National Instruments (12 bit,
1.25 MHz) data acquisition system and Labview. In this
paper, all potentials are quoted versus the saturated calomel
electrode (SCE). For capacity experiments, the cell was
stimulated with an AC waveform (70 Hz) superimposed on
a voltage ramp (scan rate 5 mV/s). The amplitude of the AC
perturbation was 2 mV rms, smaller than in previous studies
[42] chosen for its decreased non-linear response in the
region of the pseudo-capacitance peaks. The capacity was
Fig. 1. Schematic representation of the experimental setup illustrating the
Hg drop electrode and the method of depositing a lipid monolayer.
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calculated from the out-of-phase and in-phase components
of the current assuming a series RC circuit.
Chronoamperometry was used to characterize Tl(I)
reduction in the potential region leading to and covering
the first phase transition. The Tl(I)/Tl(Hg) couple is kineti-
cally fast on the bare mercury electrode surface [52] and
inhibition of Tl+ reduction results from blocking of the
electrode surface by the adsorbed DOPC monolayer. There-
fore, changes in the characteristics of the faradaic reaction
can be used as a measure of the permeability of the DOPC
monolayer. The potential (E) was held at 0.25 V for 3 s
and then stepped to successively more negative values (up
to 1.2 V) for 1 s for both the DOPC covered and
uncovered electrode surface. Finally, the potential was
stepped to 0.2 V for 10 s to allow any Tl(Hg) to become
oxidized and diffuse out of the Hg. The current was
recorded at a 20-kHz sampling frequency with a 10-kHz
low-pass filter.
3. Results and discussion
3.1. Capacitance measurements
Characterization of the adsorbed layer relies upon capaci-
tance measurements which is a sensitive but averaging
technique. DOPC monolayer adsorbed onto Hg displays a
minimum capacitance of 1.85 AF cm2 at potentials of the
uncharged Hg surface, and any increase from this value
indicates a decrease in monolayer order or the introduction
of defects. Potential-induced phase changes are also
observed and are a sensitive measure of monolayer order.
These phase changes are manifested as pseudo-capacitance
peaks (0.965 and 1.025 V/SCE). Previous work [42] has
shown that the phase change was preceded by potential-
induced defect formation, from which the new phase starts
to grow. The potential range through which the phase
change occurs will depend upon the energetics of the growth
of the new phase from the potential-induced defects. If all
defects are energetically homogeneous, which would be
expected for a well-ordered phase, the phase change will
occur at a single value of the potential. If the monolayer is
disordered, the potential-induced defects will be energeti-
cally heterogeneous and the phase change will occur over a
range of potentials, causing the pseudo-capacitance peaks to
be broad and less intense. The height of the peaks is
therefore a sensitive indication of the lipid monolayer
organization. The lipid monolayer organization was inter-
rogated through the measurement of the pseudo-capacitance
peaks (phase change kinetics) and minimum capacitance of
the monolayer. These two criteria allow us to indirectly
probe interaction of DOPC with the AmB formulations, and
the corresponding control solutions. We expect that inter-
action with the DOPC head groups may not change the
minimum capacitance significantly, but would result in
modification of the capacitance peaks. On the other hand,
direct insertion into the DOPC monolayer would increase
the minimum capacitance of the layer, as well as decrease
the height of the phase transition peaks.
The differential capacitance–potential measurements are
shown in Fig. 2 for DOPC alone, and with additions of 80%
of therapeutic dose of deoxycholate, FZ, HFZ, Abelcet, and
Abelcet blank. The DOPC layer was deposited onto the Hg
electrode at 0.4 V/SCE and the potential is scanned
negatively up to 1.2 V/SCE, just beyond the capacitance
peaks which signal the phase changes. These curves are
shown in solid line and represent the as-deposited layer
characteristics. In other words, the DOPC layer deposited
onto the Hg drop is representative of the layer on the gas/
solution interface after exposure to the subphase with
additions of drug. The floating DOPC monolayer (at Pe)
is well organized (i.e. not significantly perturbed) and
interaction with AmB models the interaction with a cell
membrane that is free of defects or pores. Scanning the
potential negatively introduces a stress (potential) to the
system which is used to interrogate the integrity of the
deposited monolayer. The layer becomes porated and
strongly defective at these negative potentials containing
many holes/defects with which AmB can interact. The
potential is then scanned positively, back to the initial value
of potential and the characteristics of the reformed layer
measured (represented by the dashed line in Fig. 2). This
scan is representative of the reformation of a possibly
defect-free lipid layer from a lipid layer that was stressed
and defective. Reforming the defect-free monolayer will be
hampered by incorporation or interaction with the drug,
which will be apparent in the height of the capacitive peaks
and via the minimum capacitance measurements.
The DOPC layer (Fig. 2c) has a stable minimum capaci-
tance of 1.85 AF cm2 and a peak height of 100 AF cm2 for
the most positive and intense peak. These two character-
istics are the same regardless of the potential scan direction,
illustrating the ideal character of this monolayer making it a
suitable choice for investigations of drug/lipid interaction.
These characteristics were always achieved before addition
of any drug to the subphase, and therefore represent a
convenient control ensuring the same starting DOPC mono-
layer. The addition of 80% of the TD of Abelcet (Fig. 2e)
into the subphase elicits a drop in the peak height for both
the as-deposited and reformed layers. The as-deposited layer
minimum capacitance was not strongly perturbed but a
slight increase in the monolayer capacitance was measured
for the reformed layer. Abelcet is composed of a lipid
complex of AmB/DMPC/DMPG, and the appropriate con-
trol of DMPC/DMPG was also examined (Fig. 2f). The
Abelcet blank measurements were identical with the base-
line DOPC results, indicating that the lipid complex in
solution had little influence on the lipid monolayer. The
changes observed for Abelcet are due to the presence of
AmB which enhances the interaction with the lipid mono-
layer. The lipid complexed AmB, and the lipid blank seem
to interact only with the DOPC head groups, thereby
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influencing the phase change but not introducing defects in
the DOPC layer at 0.4 V/SCE. Abelcet has been shown to
have low in vivo toxicity though remaining effective at the
recommended TD. These results certainly illustrate the
limited influence of this formulation on the disruption of
the pure DOPC monolayer, in contrast to the FZ results
presented below.
Fig. 2b illustrates the strong influence FZ had on the
DOPC monolayer. The capacitance of the as-formed layer is
1.9 AF cm2 which is larger than the DOPC control. The
disruption of the DOPC monolayer maybe due to a strong
interaction of non-conductive pre-pore complexes of AmB
with the membrane [9,10]. The phase change peaks are
significantly altered, decreased to 30 AF cm2 for the as-
deposited layer and were not measurable for the reformed
layer. The minimum capacitance of the reformed layer is
much larger and no longer independent of potential, having
a minimum around 0.4 V/SCE with a value of 2.2 AF
cm2. The alteration to the layer is significant. A similar
interaction of HFZ with the lipid layer was also observed
(Fig. 2a). FZ is a mixture of AmB and deoxycholate.
Therefore, a deoxycholate control was also measured (Fig.
2d). The minimum capacitance of the as-deposited layer is
the same as the DOPC control, although the peak was
reduced to 60 AF cm2. The reformed layer demonstrated
a similar decrease in peak height, but the minimum capaci-
tance remained at 1.85 AF cm2. Deoxycholate is an anionic
surface active agent that would tend to interact with the
DOPC head groups. It is evident from the capacitance
measurements that deoxycholate only interacts with the
lipid in a peripheral way, slightly influencing the poten-
tial-driven lipid phase change, but not increasing the mini-
mum capacitance. The AmB/deoxycholate complex (FZ or
HFZ) had a significant disrupting effect on the layer.
Initially, AmB strongly interacts with the lipid monolayer.
Once holes are created in the lipid layer through negative
potential excursion, AmB inserts itself into the lipid matrix
causing a significant decrease in lipid order and a large
number of defects preventing the reformation of a defect-
free DOPC monolayer.
Fig. 3 compiles capacitance peak data and minimum
capacitance data as a function of the percentage of TD or
equivalent for the five solutions used. The minimum
capacitance for the as-deposited layer increases with sub-
phase concentration for only the FZ and HFZ. The peak
capacitance changes in a more complex manner. The largest
changes observed are again for the FZ and HFZ with a sharp
decrease from 100 to 35 AF cm2. The FZ control (deox-
ycholate) also influences the peak capacitance, but in a less
dramatic manner, decreasing to 60 AF cm2. This again
indicates that the largest changes to the DOPC monolayer
were observed in the presence of AmB. In contrast to these
large changes, the Abelcet blank only causes a decrease in
the peak capacitance at the lower concentrations, but essen-
tially no significant decrease was observed. The decrease in
peak capacitance for Abelcet was larger than for the Abelcet
Fig. 2. Capacitance measured for Hg/0.1 M KCl () and DOPC-coated Hg drop in contact with 80% TD of various AmB formulations (as deposited
————, reformed - - - - - - -): (a) HFZ, (b) FZ, (c) only DOPC, (d) deoxycholate (blank solution for FZ group), (e) Abelcet, (f) Abelcet blank composed of
DMPG/DMPC. The capacitance was calculated assuming a series RC circuit, measured using 5 mV/s, 70 Hz, 2 mV rms.
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blank, similar to that observed for deoxycholate. These
results reveal that Abelcet induces smaller changes or
disorganization in the as-deposited DOPC monolayer when
compared to FZ or HFZ. These results for the as-deposited
layers can be used to estimate the effect of the drug on
sterol-free cell membranes which do not experience signifi-
cant stress which would result in weak areas within the
membrane (similar to the effect of osmotic stress).
The matrix in which the AmB exists also seems to have a
significant influence. Comparing the Abelcet and FZ blanks
clearly demonstrates this effect. Deoxycholate influences
the DOPC layer in a manner that appears similar to Abelcet
itself, while the Abelcet blank does not interact or disrupt
the lipid monolayer. These observations suggest that the
solubilizing agent may also cause significant damage to the
membrane in addition to the effect of AmB.
Scanning the potential to the negative limit introduces
pores or defects into the adsorbed lipid monolayer. Once
porated, reformation of the adsorbed layer provides further
information on the interaction of the drug with defective
regions of the DOPC monolayer. The capacitance peaks
measured for the reformed layer show that FZ and HFZ
significantly affect the readsorption of the layer. The capaci-
tance peak disappears at concentrations above 40% of the
TD. Deoxycholate also decreases the peak heights but less
efficiently than FZ or HFZ. Abelcet also strongly interacts
with the defective layer but the response is saturated at 35
AF cm2, illustrating that the lipid complexed AmB has a
limited influence on the defective monolayer. The Abelcet
blank has no influence on the reformation of the DOPC
monolayer. The excess lipid present in the Abelcet may act
to mitigate the destructive influence of AmB, or the lipid
may shield the sterol-free DOPC monolayer from interac-
tion with the complexed AmB.
Support for the general discussion above was also
observed with the minimum capacitance for the reformed
layer. The only significant increases are observed for FZ and
HFZ, while the other formulations did not modify the
capacitance of the re-formed monolayer. This suggests that
FZ and HFZ have components that are incorporated within
the lipid monolayer, while Abelcet, Abelcet blank, and
deoxycholate are displaced from the monolayer resulting
in a DOPC layer similar to that first deposited. These
indirect observations of the effect of AmB on a one-
component lipid layer, in its various formulations, are
somewhat correlated to the in vivo toxicity results [53]. In
these cases, the FZ family has a strong toxic effect on renal
cells which limits the amount of drug that can be adminis-
tered. Complexation of AmB with lipid demonstrates a
lower toxicity but maintains its efficacy though requiring
a larger dose. The lowered toxicity may result from the
buffering or healing effect of the excess lipid.
3.2. Tl reduction measurements
The capacitance measurements provide clues to origin of
the toxicity of AmB by investigating the effect of the drug on
the lipid organization in an indirect, though sensitive manner.
AmB incorporates into the cell membrane creating holes
through which the cell contents are lost, resulting in cell
death. This process has been thought to occur for sterol-
containing membranes, and for membranes lacking sterol if
under osmotic stress [22]. A porated lipid monolayer can be
characterized by measuring metal ion reduction through the
monolayer yielding the mean size and number density of the
holes assuming a random array of microelectrode model [54].
Diffusion to a microelectrode occurs in a hemispherical
fashion, yielding currents that are larger than what would
be expected for linear diffusion to an electrode of similar size.
Diffusion to an array of microelectrodes would proceed
through the initial hemispherical diffusion characteristic at
short times. Once neighboring hemispheres overlap, the
diffusion characteristic changes evolving toward linear dif-
fusion. Therefore at long times, measurement of the reduction
current would yield the same result for an uncovered elec-
trode surface, as for one covered with pinholes. The current
transient can be used to determine the average size and
density of the pinholes under constraints of the model system.
Fig. 3. Summary of capacitance data (minimum capacitance measured
between 0.6 and 0.35 V/SCE, and maximum peak capacitance) for the
various formulations of AmB: (a) the as-deposited DOPC layer, (b) the
reformed DOPC layer as a function of the fraction of TD or equivalent.
Representative errors for the capacitance measurements are shown. The
dotted line in the top panels represents the baseline capacitance values.
R. Stoodley et al. / Biochimica et Biophysica Acta 1564 (2002) 289–297294
This approach can estimate the hole radius in a restricted
range, limited by experimental factors. The smallest meas-
urablemodel pore sizes are typically 0.1 Am, due to overlap of
the capacitive and faradaic currents at short times (<5 ms).
The upper limit is determined by the time at which the
hemispherical diffusion layers sufficiently overlap resulting
in linear diffusion. For situations where the density or size of
the pinholes is large such that linear diffusion is achieved
before the short time limit, no measurement of the pore size is
possible since only linear diffusion is observed. The fraction
of the surface covered with lipid can be determined by
calculating the total area occupied by the holes. This is only
an estimate of the true coverage since metal ions can penetrate
regions of the monolayer that are thin especially with suffi-
cient overpotential [55–58]. The average radii and density of
pores are useful parameters that can be used to explore the
changes in the monolayer after interaction with the drug, but
the absolute size of the pores must be interpreted with
caution. The current transient for diffusion to an array of
microelectrodes cannot be easily distinguished from a current
transient for a chemical step preceding an electron transfer.
This CE reaction has been used in the study of transport
through Gramicidin incorporated into a DOPC monolayer
which was adsorbed onto Hg [59,60]. The complexation of
Tl+ by Gramicidin can be considered as the chemical step
before the reduction. This CE process is reasonably expected
for Gramicidin since it is a selective ion channel. Without
specific information on binding sites for cations in the AmB
pore, we limited our analysis to a simple determination of the
size and density of pores, keeping in mind that the possibility
of aggregation of smaller pores into larger patches cannot be
distinguished from a patch-sized pore.
Characterization of the porosity of the layers as a
function of the transmembrane potential allowed for inves-
tigation of the effect of potential on the integrity of the
adsorbed lipid layer, and the influence the drug had on these
monolayers. Fig. 4 shows the current–potential relationship
50 ms after the potential step as a function of 80% TD of
the drug formulations (Fig. 4a is the Abelcet group, Fig. 4b
the FZ group). All currents are normalized to the linear
diffusion limited value. In both Fig. 4a and b, the pure
DOPC layer blocks the Tl+ transport until 100 mV positive
of the potential-induced phase transition, where the current
quickly increases to match the diffusion-limited value. No
transport of Tl+ through the DOPC layer was measured for
potentials even 300 mV negative of the reversible potential
(f450 mV) illustrating the highly organized defect-free
nature of the DOPC monolayer on Hg. This has been
reported previously [42]. The increase in the current flowing
through the DOPC layer modified by interaction with the
drug in the subphase directly indicates the porosity of the
lipid monolayer. As seen in Fig. 4a, the Abelcet blank
slightly positively shifts the break through potential. Abelcet
also positively shifts the break through potential. No sig-
nificant changes were observed for the Abelcet group in the
potential region before the onset of the phase transition. This
supports the minimum capacity measurements that indicate
an undisturbed DOPC monolayer at these potentials. Fig. 4b
illustrates the significant changes brought about by inter-
action of DOPC with the FZ group. The deoxycholate blank
has an impact on the porosity of the DOPC monolayer in a
similar fashion as observed for Abelcet. A more significant
shift in the break through potential was observed for FZ
indicating that the monolayer was defected or poorly organ-
ized due to interaction with FZ. Interaction with the HFZ
resulted in a very porous layer with significant current
measured at potentials just negative of the reversible Tl
reduction potential. This has been observed previously for
Tl+ transport through incorporated Gramicidin [42].
Quantification of these observations was accomplished
by fitting the random hole model to the current transients
resulting in values for the mean radius of the pore (ractive),
the average density of pores (N) and the fraction of surface
covered by lipid (H). These parameters are plotted in Fig. 5
as a function of the TD for a potential near the complete
opening of the layer, 850 mV/SCE. The error bars
represent the average standard deviation for each set of data
except HFZ (which is explained later). At this potential, the
greatest changes due to interaction with the drug are
observed. The data are separated into the Abelcet and FZ
groups, and characterize the as-formed layers. The Abelcet
group consists of the lipid blank and Abelcet. Abelcet
displays slightly larger holes and density of holes than does
the blank. In both cases, the size of the holes increase with
%TD, and the density slightly decreases. The calculated
coverage of lipid is close to 1 for the blank, but a con-
sistently smaller coverage was measured for Abelcet. In
Fig. 4. Normalized Tl+ reduction currents for a DOPC-coated Hg drop in
contact with various formulations of AmB (80% of TD or equivalent). The
capacitance of the DOPC monolayer is shown for reference (- - - - -). 5 No
DOPC, o DOPC, n deoxycholate, FZ, z HFZ, y Abelcet blank, .
Abelcet.
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fact, a decrease in lipid coverage was observed for Abelcet
at the 30% TD value. A similar change was observed for the
capacitive peak maximum measurements presented in Fig. 3
where the strongest decrease in peak height was observed
around this value. This suggests that Abelcet/DOPC may
interact strongly at this ratio introducing holes or defects in
the monolayer. The measured pores are 5–15 Am in size
which is similar to the structures observed in lipid mono-
layers at the gas/solution interface [61,62] suggesting that
the pores measured using our technique may represent
porous patches within our lipid monolayer. Recent AFM
measurements of AmB interaction with lipid bilayer on mica
also report regions <1 Am in diameter that are believed to be
AmB pores [11]. Many of these structures exist close
together possibly creating an even larger patch similar to
our measurements.
The FZ group contains the fitting results for deoxycho-
late, FZ and HFZ. The data presented in Fig. 5b do not
cover the full TD range. The FZ and HFZ at high TD
( > 50%) are very porous and linear diffusion profiles result
preventing an estimate of the coverage or hole size and
density. For coverage values below f0.5, large deviations
in the fitting parameters were observed and therefore the
average standard deviation for HFZ is not shown. Deoxy-
cholate was only characterized to 80%TD. Deoxycholate
interacted with the DOPC monolayer yielding hole radii and
densities similar to that observed for Abelcet. An increase in
hole size was observed for TD values greater than 40%, also
reflected in the coverage. FZ gave values very similar to
deoxycholate, though the layer was less porous at 40% TD.
Above this value of TD, the lipid layer was strongly porated.
The largest disturbance in the integrity of the monolayer was
observed for HFZ. The average hole size sharply increased
for values above 20% TD. The hole density was larger than
deoxycholate and FZ, but only slightly. The coverage
strongly declined starting at 20% TD. These data illustrate
the disruptive effect of HFZ on a pure DOPC monolayer,
disrupting and porating the DOPC monolayer at moderate
fractions of the TD or equivalent. FZ is heat treated to
reduce toxicity, but our HFZ results demonstrate a larger
disruptive influence on pure DOPC monolayer as compared
to FZ. In contrast to the toxicity studies on HFZ, our
measurements were performed on sterol-free lipid mono-
layers. The future addition of sterol into the lipid monolayer
will allow us to probe the sterol/AmB hypothesis. These
experiments are in progress.
The Tl data correlate well with the capacitance observa-
tions described previously. In both blank tests, the lipid
monolayer was essentially unchanged for Abelcet blank,
and moderately disrupted in the presence of deoxycholate.
Abelcet does interact with the DOPC monolayer at inter-
mediate TD values, but generally, the DOPC monolayer
remained intact. FZ and HFZ had the largest destructive
effects on lipid monolayer, and for values >40% TD, the
lipid layer was destroyed, offering no impediment to metal
ion reduction. In all cases, the formulation containing AmB
was significantly more disruptive to the DOPC monolayer
than the corresponding blank experiments, illustrating that
AmB is a major contributor to the disorganization and
destruction of the lipid layer.
4. Conclusions
A model system was used to study the interaction of
three formulations of AmB with a lipid monolayer. The
character of the interaction was interrogated utilizing elec-
trochemical techniques sensitive to the organizational state
of the lipid monolayer. The model system was sensitive to
changes in the lipid layer due to the interaction with various
formulations of AmB. The largest disruptive interaction was
observed for the FZ and HFZ formulations. Deoxycholate
(FZ blank) weakly interacted with the lipid layer, signifi-
cantly less than when present with AmB. The lipid AmB
complex, Abelcet, demonstrated a much lower disruptive
effect toward the lipid monolayer, although the amount of
AmB in the subphase was 10 times larger when compared to
FZ. The Abelcet blank did not significantly influence the
character of the DOPC monolayer. The lipid present in the
Abelcet may have a shielding, annealing and/or healing
effect that buffers the disruption due to the presence of
AmB. Utilizing this model system, we plan to investigate
the interaction of these formulations of AmB with DOPC
layers modified by the addition of cholesterol and ergo-
Fig. 5. Calculated pore size (bottom), density (middle) and lipid coverage
(top) for the various formulations of AmB as a function of the fraction of
TD or equivalent: n deoxycholate, FZ, z HFZ, y Abelcet blank, .
Abelcet.
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sterol. The activity of AmB toward the sterol-containing
monolayer and as a function of formulation of the drug will
be measured. Interrogation of AmB/sterol/lipid interactions
by capacitance and measurement of pore sizes and density
will be performed and compared to these sterol-free meas-
urements.
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